Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
BOJ Governor Ueda Highlights Uncertainty Over Future Interest Rate Hikes 
Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
Microchip Technology Boosts Q3 Outlook on Strong Bookings Momentum 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Europe Confronts Rising Competitive Pressure as China Accelerates Export-Led Growth 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Samsung Biologics and Biogen, an American biotechnology company, based in Cambridge, Massachusetts, signed a deal for the transfer of stake in Samsung Boiepis. The South Korean biotech firm headquartered in Songdo, Incheon, is buying all of Biogen’s stake in the biopharma company.
Samsung Bioepis was formed in 2012 via a joint venture between Samsung Biologics and Biogen. The latter owned a 15% stake at first, and in 2018, the percentage was increased to 50% as it extended its controlling rights in the company.
As per The Korea Herald, the acquisition of Biogen’s stake is predicted to help boost Samsung Biologic’s competitiveness in the global bio market. The value of the deal is ₩2.7 trillion or around $2.3 billion.
The total shares acquired are 10,341,852 units, and Samsung Biologics stated that the company’s board of directors approved the transaction. The payments for the stakes are set to be made in installments and will be paid over the next two years.
The full ownership of the shares will take effect once the first payment of $1 billion is completed. It was revealed that it was Biogen that forwarded a request for the buyout deal. Despite the acquisition, both companies said they would continue to work as close partners.
“We are thankful to Samsung Biologics for a productive collaboration since 2012,” Biogen’s chief executive officer, Michel Vounatsos, said in a press release. “We believe biosimilars are essential to help sustain healthcare systems and represent an important value creation opportunity for Biogen.”
With the transaction, Samsung Biologics Co. will take over and be in full control of Samsung Bioepis Co. since the deal is for the entire holdings of Biogen’s shares. Pulse News reported that the transfer of shares is set to take place on April 30, 2022.
Meanwhile, Samsung Bioepis is currently developing five biosimilar drugs that it will be launching worldwide. One of them is just waiting for approval and ready for marketing. The four other drugs are in the third phase of clinical trials. Two of the medicines are for oncology, and three are formulated for autoimmune.
